Health insurance coverage changing? Call 1.800.4HUMIRA or click to see how we can help ▸
You’ll find useful information about pediatric inflammatory bowel diseases (IBD), including ulcerative colitis, and how treatment with HUMIRA may help. Bring the brochure with you to discuss with the doctor at your child’s next appointment.
The goal of pediatric ulcerative colitis (UC) treatment is remission—few or no symptoms. With HUMIRA, remission is possible for children 5 years of age and older.
In a clinical study among pediatric patients from 5 to 17 years of age with moderate to severe ulcerative colitis, a majority of patients on HUMIRA achieved remission after just 8 weeks. Individual results may vary.
Many children who responded to treatment by week 8 were in remission at 1 year. Additionally, a majority of children responding by week 8 continued to have symptom relief at 1 year. Individual results may vary.
Director of the Inflammatory Bowel Disease Clinic and Professor of Medicine at University of Calgary
Recommended for you:
*Nurse Ambassadors are provided by AbbVie and do not work under the direction of your health care professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.
HUMIRA is a prescription medicine used to treat moderate to severe ulcerative colitis in adults and children 5 years of age and older. It is not known if HUMIRA is effective in people who stopped responding to or could not tolerate TNF-blocker medicines.
You should discuss the potential benefits and risks of HUMIRA with your doctor. HUMIRA is a TNF blocker medicine that can lower the ability of your immune system to fight infections. You should not start taking HUMIRA if you have any kind of infection unless your doctor says it is okay.
Tell your doctor about all of your health conditions, including if you:
Also tell your doctor about all the medicines you take. You should not take HUMIRA with ORENCIA® (abatacept), KINERET® (anakinra), REMICADE® (infliximab), ENBREL® (etanercept), CIMZIA® (certolizumab pegol), or SIMPONI® (golimumab). Tell your doctor if you have ever used RITUXAN® (rituximab), IMURAN® (azathioprine), or PURINETHOL® (mercaptopurine, 6-MP).
HUMIRA can cause serious side effects, including:
Call your doctor or get medical care right away if you develop any of the above symptoms.
Common side effects of HUMIRA include injection site reactions (pain, redness, rash, swelling, itching, or bruising), upper respiratory infections (sinus infections), headaches, rash, and nausea. These are not all of the possible side effects with HUMIRA. Tell your doctor if you have any side effect that bothers you or that does not go away.
HUMIRA is given by injection under the skin.
This is the most important information to know about HUMIRA. For more information, talk to your health care provider.
Uses
HUMIRA is a prescription medicine used:
US-HUM-210186
Please see the Full Prescribing Information, including the Medication Guide, for HUMIRA.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.
Legal Notices/Privacy Policy. Copyright 2021, AbbVie Inc., North Chicago, Illinois, U.S.A. If you have any questions about AbbVie’s HUMIRA.com website that have not been answered click here. This website and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient.
Reference: 1. HUMIRA Injection [package insert]. North Chicago, IL: AbbVie Inc.
